ImmunityBio's Anktiva Sparks 700% Sales Leap and Global Approvals
TL;DR
ImmunityBio (IBRX) stock jumped over 30% after 2025 preliminary results showed Anktiva sales up about 700% year-over-year to roughly $113 million, with Q4 2025 revenue up 431% to $38.3 million. Regulatory wins expanding Anktiva’s reach include Saudi approvals for NSCLC combinations and for bladder cancer with BCG, while Phase 2b enrollment for first-line bladder cancer is progressing. Analysts sketch a bullish picture with a Strong Buy rating and a roughly $7.33 price target, implying substantial upside potential.
- ImmunityBio Stock (IBRX) Rockets Higher after Reporting 700% Growth in Anktiva Sales TipRanks
- ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG Yahoo Finance
- ImmunityBio: Why I Am Upgrading To A Buy For 2026 (NASDAQ:IBRX) Seeking Alpha
- Patrick Soon-Shiong’s cancer drug approved by Saudi FDA NewsNation
- Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% The Motley Fool
Want the full story? Read the original reporting
Read on TipRanks